Ocuphire Pharma Reaches New 52-Week High of $4.82

Ocuphire Pharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 4.82 on March 5, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 180.59% rise over the past year, significantly outpacing the S&P 500's performance of 18.89% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Ocuphire Pharma has a market capitalization of USD 234 million. Despite its notable stock performance, the company remains in a loss-making position, with a negative price-to-earnings ratio and a return on equity of -577.66%. The stock's price-to-book ratio stands at 39.18, indicating a premium valuation relative to its book value. The company's financial metrics, including a debt-to-equity ratio of -4.99 and a dividend yield of 0.00%, further illustrate its current standing in the market. The stock's previous 52-week low was recorded at USD 0.65, highlighting the significant upward movement it has experienced.